Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension

Ningli Wang,1 Da-Wen Lu,2 Yingzi Pan,3 Yury Astakhov,4 Tatyana Iureva,5 Adeniyi Adewale,6 Thomas M Walker6 1Beijing Tongren Eye Center, Beijing, People’s Republic of China; 2Tri-Service General Hospital, Taipei, Taiwan; 3Peking University First Hospital, Beijing, People’s Republi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang N, Lu DW, Pan Y, Astakhov Y, Iureva T, Adewale A, Walker TM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	brinzolamide/brimonidine fixed-dose combination intraocular pressure reduction ocular hypertension open-angle glaucoma Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3403209442a449eebb388597ae879da9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3403209442a449eebb388597ae879da9
record_format	dspace
spelling	oai:doaj.org-article:3403209442a449eebb388597ae879da92021-12-02T09:12:18ZComparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension1177-5483https://doaj.org/article/3403209442a449eebb388597ae879da92020-01-01T00:00:00Zhttps://www.dovepress.com/comparison-of-the-intraocular-pressure-lowering-efficacy-and-safety-of-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Ningli Wang,1 Da-Wen Lu,2 Yingzi Pan,3 Yury Astakhov,4 Tatyana Iureva,5 Adeniyi Adewale,6 Thomas M Walker6 1Beijing Tongren Eye Center, Beijing, People’s Republic of China; 2Tri-Service General Hospital, Taipei, Taiwan; 3Peking University First Hospital, Beijing, People’s Republic of China; 4Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia; 5Irkutsk Branch of the Academician S.N. Fyodorov Eye Microsurgery Federal State Institution, Irkutsk, Russia; 6Novartis Pharmaceuticals Corporation, Fort Worth, TX, USACorrespondence: Ningli WangBeijing Tongren Eye Center, No. 1 Dongjiaomin Str., Dongcheng District, Beijing 100041, People’s Republic of ChinaTel +861058265922Email wningli@vip.163.comObjective: To demonstrate that the intraocular pressure (IOP)-lowering efficacy of a twice-daily brinzolamide 10 mg/mL (BRINZ)/brimonidine 2 mg/mL (BRIM) fixed-dose combination (BBFC) was non-inferior to its individual components (BRINZ+BRIM) dosed concomitantly in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Safety was also evaluated.Methods and Analysis: This was a Phase III, multicenter, observer-masked study in patients from China, Russia and Taiwan. Patients aged ≥ 18 years with a mean IOP ≥ 21 mmHg and ≤ 36 mmHg in the same eye after washout of other IOP-lowering medications were included. Eligible patients were randomized (1:1) to receive BBFC or BRIZ+BRIM eye drops twice daily for 3 months. The primary endpoint was the mean change in diurnal IOP (averaged over 09:00, +2 h, and +7 h) from baseline to Month 3. Adverse events (AEs) were recorded throughout the study.Results: The per-protocol set included 349 patients (BBFC, n=172; BRINZ+BRIM, n=177). The mean±standard deviation diurnal IOP at baseline was 24.6± 2.66 mmHg in both groups. At Month 3, the least square mean±standard error change in diurnal IOP from baseline was − 7.2± 0.34 mmHg and − 7.3± 0.34 mmHg with BBFC and BRINZ+BRIM, respectively (between-group difference: 0.1 mmHg [95% CI − 0.5, 0.7]). In the BBFC and BRINZ+BRIM groups, 53.3% and 55.0% of patients achieved a diurnal IOP < 18 mmHg, and 43.2% and 37.4% of patients, respectively, achieved a mean diurnal IOP reduction > 30% from baseline at Month 3. Ocular AEs were reported in 28.7% (BBFC) and 22.5% (BRINZ+BRIM) of patients; conjunctival hyperemia was the most frequent ocular AE (BBFC, 6.4%; BRINZ+BRIM, 6.8%). Non-ocular AEs were reported in 32.4% (BBFC) and 30.4% (BRINZ+BRIM) of patients.Conclusion: The study findings demonstrate that the efficacy of twice-daily BBFC was non-inferior to BRINZ+BRIM in patients with OAG/OHT. The safety profile of BBFC was similar to that of BRINZ+BRIM.Keywords: brinzolamide/brimonidine fixed-dose combination, intraocular pressure reduction, ocular hypertension, open-angle glaucomaWang NLu DWPan YAstakhov YIureva TAdewale AWalker TMDove Medical Pressarticlebrinzolamide/brimonidine fixed-dose combinationintraocular pressure reductionocular hypertensionopen-angle glaucomaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 221-230 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	brinzolamide/brimonidine fixed-dose combination intraocular pressure reduction ocular hypertension open-angle glaucoma Ophthalmology RE1-994
spellingShingle	brinzolamide/brimonidine fixed-dose combination intraocular pressure reduction ocular hypertension open-angle glaucoma Ophthalmology RE1-994 Wang N Lu DW Pan Y Astakhov Y Iureva T Adewale A Walker TM Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
description	Ningli Wang,1 Da-Wen Lu,2 Yingzi Pan,3 Yury Astakhov,4 Tatyana Iureva,5 Adeniyi Adewale,6 Thomas M Walker6 1Beijing Tongren Eye Center, Beijing, People’s Republic of China; 2Tri-Service General Hospital, Taipei, Taiwan; 3Peking University First Hospital, Beijing, People’s Republic of China; 4Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia; 5Irkutsk Branch of the Academician S.N. Fyodorov Eye Microsurgery Federal State Institution, Irkutsk, Russia; 6Novartis Pharmaceuticals Corporation, Fort Worth, TX, USACorrespondence: Ningli WangBeijing Tongren Eye Center, No. 1 Dongjiaomin Str., Dongcheng District, Beijing 100041, People’s Republic of ChinaTel +861058265922Email wningli@vip.163.comObjective: To demonstrate that the intraocular pressure (IOP)-lowering efficacy of a twice-daily brinzolamide 10 mg/mL (BRINZ)/brimonidine 2 mg/mL (BRIM) fixed-dose combination (BBFC) was non-inferior to its individual components (BRINZ+BRIM) dosed concomitantly in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Safety was also evaluated.Methods and Analysis: This was a Phase III, multicenter, observer-masked study in patients from China, Russia and Taiwan. Patients aged ≥ 18 years with a mean IOP ≥ 21 mmHg and ≤ 36 mmHg in the same eye after washout of other IOP-lowering medications were included. Eligible patients were randomized (1:1) to receive BBFC or BRIZ+BRIM eye drops twice daily for 3 months. The primary endpoint was the mean change in diurnal IOP (averaged over 09:00, +2 h, and +7 h) from baseline to Month 3. Adverse events (AEs) were recorded throughout the study.Results: The per-protocol set included 349 patients (BBFC, n=172; BRINZ+BRIM, n=177). The mean±standard deviation diurnal IOP at baseline was 24.6± 2.66 mmHg in both groups. At Month 3, the least square mean±standard error change in diurnal IOP from baseline was − 7.2± 0.34 mmHg and − 7.3± 0.34 mmHg with BBFC and BRINZ+BRIM, respectively (between-group difference: 0.1 mmHg [95% CI − 0.5, 0.7]). In the BBFC and BRINZ+BRIM groups, 53.3% and 55.0% of patients achieved a diurnal IOP < 18 mmHg, and 43.2% and 37.4% of patients, respectively, achieved a mean diurnal IOP reduction > 30% from baseline at Month 3. Ocular AEs were reported in 28.7% (BBFC) and 22.5% (BRINZ+BRIM) of patients; conjunctival hyperemia was the most frequent ocular AE (BBFC, 6.4%; BRINZ+BRIM, 6.8%). Non-ocular AEs were reported in 32.4% (BBFC) and 30.4% (BRINZ+BRIM) of patients.Conclusion: The study findings demonstrate that the efficacy of twice-daily BBFC was non-inferior to BRINZ+BRIM in patients with OAG/OHT. The safety profile of BBFC was similar to that of BRINZ+BRIM.Keywords: brinzolamide/brimonidine fixed-dose combination, intraocular pressure reduction, ocular hypertension, open-angle glaucoma
format	article
author	Wang N Lu DW Pan Y Astakhov Y Iureva T Adewale A Walker TM
author_facet	Wang N Lu DW Pan Y Astakhov Y Iureva T Adewale A Walker TM
author_sort	Wang N
title	Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
title_short	Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
title_full	Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
title_fullStr	Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
title_full_unstemmed	Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
title_sort	comparison of the intraocular pressure-lowering efficacy and safety of the brinzolamide/brimonidine fixed-dose combination versus concomitant use of brinzolamide and brimonidine for management of open-angle glaucoma or ocular hypertension
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/3403209442a449eebb388597ae879da9
work_keys_str_mv	AT wangn comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension AT ludw comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension AT pany comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension AT astakhovy comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension AT iurevat comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension AT adewalea comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension AT walkertm comparisonoftheintraocularpressureloweringefficacyandsafetyofthebrinzolamidebrimonidinefixeddosecombinationversusconcomitantuseofbrinzolamideandbrimonidineformanagementofopenangleglaucomaorocularhypertension
_version_	1718398177473724416

Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension

Ejemplares similares